C
인벤테라
0007J0KOSDAQ자연과학 및 공학 연구개발업48.5 / 100
Reference Date: 2026-06-10
Financial Score16.5 / 40
News Sentiment20.0 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 43.0% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Invenia is a biopharmaceutical company developing the 'Invinity™' polysaccharide-based nanotechnology platform to inhibit protein corona formation, enhance intrabody stability, and enable targeted drug delivery. The company focuses on addressing unmet medical needs through alternative MRI contrast agents and nano-medicines administered via oral or intra-articular injection methods.
Number of Employees
18people
Average Salary
78.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
6.21Industry Average 3.241.0Point
1.9x industry avg (risky)
ROE
-45.55Industry Average -32.093.5Point
In line with industry avg
Debt Ratio
3.92Industry Average 7.315.0Point
Lower than industry avg (good)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 80
- Negative피스피스스튜디오, 수요예측 참패?확약률 5.6%
피스피스스튜디오의 코스닥 상장 청약에서 기관 수요예측이 참패하여 의무보유 확약률이 낮아져 부정적 영향 예상.
- Positive인벤테라, 나노-MRI 조영제 'INV-002' 임상 3상 중간결과 확...
인벤테라의 나노-MRI 조영제 신약 INV-002 임상 3상 중간 결과 성공으로 상용화 기대감 상승.
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 11,270Won52-week high 35,25052-week low 11,270
1-month return0.0Point
1m -43.05% (strong drop)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral분기보고서 (2026.03)2026-05-15